This report highlights current medical guidelines and recent trends in targeted pharmaceuticals for the management of acute radiation syndrome.
Recent ARS drug approvals may inform emergency protocols; leaves open optimal international collaboration on guidelines.
The acute radiation syndrome (ARS) constitutes the most challenging, immediate medical consequence of exposure to high doses of ionizing radiation in an emergency situation. This report highlights some of the currently available medical guidelines and recommendations on the clinical management of ARS, comments recent trends regarding the approval of targeted pharmaceuticals for ARS, and suggests further initiatives for international collaboration aiming at continuously updating the medical knowledge base of this syndrome.
No takes yet. Share an insight, caveat, or question.
Stenke et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: